Category Archives: Events

Latest From Events

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

More than a Quarter of 2013 US-Based Biotech IPOs Call California Home

BIO CONVENTION LOGO_VERTICAL_D_CMYK

And of those 39 US-based biotech companies, five of them are from San Diego, highlighting the region’s growing importance as hub for the biotech and life science industries. According to a recently authored BIO article in the Union Tribune San Diego, there are several reasons at play for the strong public offerings – enactment of the JOBS Act, an eager investor market and increasing regulatory transparency resulting from PDUFA V. As powerful as the JOBS Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO CEO Company Snapshot: Conatus Pharmaceuticals

Conatus-Pharma

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February. The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. What is your company’s lead product or technology? Conatus’s lead product is emricasan, a first-in-class oral Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

What’s In Store for Biotechs at this Year’s CEO & Investor Conference

CEO2014_blog copy

In just a few weeks, industry leaders will gather in New York for one of BIO’s largest and most successful events, the 16th Annual BIO CEO & Investor Conference. As we’ve seen at JPMorgan, the extraordinary performance of biotech equities for the past several years has generated a great deal of interest among investors to work with biotech companies to foster innovation in the coming year. This year’s event is shaping up to be even Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,